This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary IL-34 Therapeutic Antibody Development
Background of IL-34
IL-34 has emerged as a potential therapeutic target, offering new avenues for the treatment of inflammatory diseases and certain types of cancers in companion animals. BioVenic provides comprehensive services for the development of veterinary IL-34 therapeutic antibodies, encompassing the entire development process and assisting in facilitating a deeper understanding of IL-34 in companion animal diseases.
Background of IL-34
| Full Name | Interleukin 34 |
|---|---|
| Aliases | C16orf77, IL34. |
| Target Profile | IL-34 is a secreted homodimeric glycoprotein that shares structural and functional similarities with CSF-1. It plays a crucial role in regulating the development and function of macrophages and monocytes and is intimately involved in maintaining immune balance and tissue homeostasis. Activation of receptors mediated by IL-34 can induce various signaling pathways that influence proliferation, survival, migration, polarization, and differentiation. |
MoA of IL-34
The expression of IL-34 can be induced by a variety of factors, including pro-inflammatory cytokines, pPAMPs, viral infections, and chemical stimuli. Upon binding with CSF-1R, IL-34 activates multiple signaling pathways, including NF-κB, c-JNK, p38 MAPK, and ERK1/2. Additionally, IL-34 can trigger autophagy by activating AMPK/ULK1 and induces the activation of paxillin and FAK by binding with PTP-ζ. By playing a key role in regulating various cellular functions, IL-34 impacts cell differentiation, movement, adhesion, metabolism, proliferation, and survival.
Fig.1 Schematic diagram of IL-34 signaling pathways.1
Application in Veterinary Therapeutics
IL-34 is a promising therapeutic target for canine atopic dermatitis, as its serum concentration in canine with this condition is significantly higher compared to control groups and correlates with clinical severity and itchiness. Highly conserved across vertebrates, IL-34 has been implicated in a range of diseases, including various inflammatory and autoimmune disorders, as well as certain types of cancer, in different species. Its overexpression in certain tumor microenvironments has been linked to promoting tumor growth by modulating tumor-associated macrophages and creating an immunosuppressive milieu. Utilizing IL-34 antibodies to block the IL-34 pathway holds the potential to treat multiple related diseases in companion animals.
Veterinary IL-34 Therapeutic Antibody Development Services
Aberrant expression of IL-34 can induce a variety of immune-related diseases and certain types of tumors in companion animals. Recognizing the potential for disease treatment by targeting this pathway, BioVenic offers veterinary therapeutic antibody development services. Our services encompass the entire process from target identification to antibody design, expression, purification, and functional validation, ensuring high affinity and specificity of the antibodies and their effective recognition and binding to IL-34.
Please click the link below for more information about our veterinary IL-34 therapeutic antibody development services.
Why Choose Us?
BioVenic provides comprehensive veterinary therapeutic antibody development services, covering from gene synthesis and animal immunization to antibody production and purification.
We focus on providing targeted solutions based on the specific needs of different animal species, offering species-specific antibody development to meet the needs of companion animals.
Throughout our service process, we emphasize strict quality control to ensure the developed therapeutic antibodies have optimal purity and stability.
IL-34 plays an effective immunoregulatory role in pathological states such as autoimmune diseases, cancer, and inflammatory disorders. BioVenic provides veterinary IL-34 therapeutic antibody development services, helping explore the potential of this target in treating a wide range of diseases in companion animals. Our one-stop service offers comprehensive support to clients, aiming to assist in developing high-quality antibodies that address a broad spectrum of diseases. If you have a development need targeting IL-34, please feel free to contact us for more information!
References
- Ge, Yun, et al. "Immunomodulation of interleukin-34 and its potential significance as a disease biomarker and therapeutic target." International Journal of Biological Sciences 15.9 (2019): 1835.
- Gow, Deborah J., et al. "Measurement of serum Interleukin 34 (IL‐34) and correlation with severity and pruritus scores in client‐owned dogs with atopic dermatitis." Veterinary Dermatology 31.5 (2020): 359-e94.